Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease.
Herrera M, Söderberg M, Sabirsh A, Valastro B, Mölne J, Santamaria B, Valverde AM, Guionaud S, Heasman S, Bigley A, Jermutus L, Rondinone C, Coghlan M, Baker D, Quinn CM.
Herrera M, et al. Among authors: santamaria b.
Am J Physiol Renal Physiol. 2017 Apr 1;312(4):F748-F759. doi: 10.1152/ajprenal.00179.2016. Epub 2016 Jul 20.
Am J Physiol Renal Physiol. 2017.
PMID: 27440778
Free article.